GT201700231A - Azabenzimidazoles y su uso como moduladores del receptor ampa - Google Patents

Azabenzimidazoles y su uso como moduladores del receptor ampa

Info

Publication number
GT201700231A
GT201700231A GT201700231A GT201700231A GT201700231A GT 201700231 A GT201700231 A GT 201700231A GT 201700231 A GT201700231 A GT 201700231A GT 201700231 A GT201700231 A GT 201700231A GT 201700231 A GT201700231 A GT 201700231A
Authority
GT
Guatemala
Prior art keywords
azabenzimidazoles
receiver modulators
ampa
ampa receiver
compounds
Prior art date
Application number
GT201700231A
Other languages
English (en)
Inventor
K Ameriks Micahel
G B Berry Cynthia
Chen Gang
Loic Jourdan Fabrice
Patrick Lebold Terry
Wei LIN David
Angel Pena Piñon Miguel
Ravula Suchitra
M Savall Bradley
M Swanson Devin
Wu Dongpei
Zhang Wei
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of GT201700231A publication Critical patent/GT201700231A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

EN LA PRESENTE INVENCIÓN SE PROPORCIONAN COMPUESTOS DE LA FÓRMULA (I) Y SALES FARMACÉUTICAMENTE ACEPTABLES, N-ÓXIDOS O SOLVATOS DE ESTOS. ADEMÁS, SE PROPORCIONAN EN LA PRESENTE INVENCIÓN COMPOSICIONES FARMACÉUTICAS QUE COMPRENDEN COMPUESTOS DE LA FÓRMULA (I) Y MÉTODOS PARA USAR LOS COMPUESTOS DE LA FÓRMULA (I).
GT201700231A 2015-04-29 2017-10-27 Azabenzimidazoles y su uso como moduladores del receptor ampa GT201700231A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562154313P 2015-04-29 2015-04-29

Publications (1)

Publication Number Publication Date
GT201700231A true GT201700231A (es) 2018-12-20

Family

ID=56008859

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201700231A GT201700231A (es) 2015-04-29 2017-10-27 Azabenzimidazoles y su uso como moduladores del receptor ampa

Country Status (39)

Country Link
US (5) US11312712B2 (es)
EP (3) EP4144736B1 (es)
JP (2) JP6800886B2 (es)
KR (2) KR102782808B1 (es)
CN (1) CN107835814B (es)
AR (1) AR104447A1 (es)
AU (2) AU2016255434C1 (es)
BR (2) BR112017023147B1 (es)
CA (1) CA2983826A1 (es)
CO (1) CO2017011017A2 (es)
CR (1) CR20170484A (es)
CY (1) CY1124059T1 (es)
DK (1) DK3288940T5 (es)
EA (1) EA033281B1 (es)
EC (1) ECSP17074645A (es)
ES (1) ES2865330T3 (es)
GT (1) GT201700231A (es)
HR (1) HRP20210403T1 (es)
HU (1) HUE053943T2 (es)
IL (1) IL254848B (es)
JO (1) JO3654B1 (es)
LT (1) LT3288940T (es)
MA (1) MA41988B1 (es)
MD (1) MD3288940T2 (es)
MX (1) MX376113B (es)
MY (1) MY194104A (es)
NI (1) NI201700129A (es)
PH (1) PH12017501816B1 (es)
PL (1) PL3288940T3 (es)
PT (1) PT3288940T (es)
RS (1) RS61688B1 (es)
SG (1) SG11201708190UA (es)
SI (1) SI3288940T1 (es)
SM (1) SMT202100222T1 (es)
TW (1) TWI706952B (es)
UA (1) UA120304C2 (es)
UY (1) UY36654A (es)
WO (1) WO2016176460A1 (es)
ZA (1) ZA201708065B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20210403T1 (hr) 2015-04-29 2021-10-29 Janssen Pharmaceutica Nv Azabenzimidazoli i njihova uporaba kao modulatora ampa receptora
AU2016255431B2 (en) * 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
JP2020524512A (ja) 2017-06-21 2020-08-20 アイセル・ジーン・セラピューティクス・エルエルシー キメラ抗体受容体（ＣＡＲｓ）の組成物およびその使用方法
CN107383004B (zh) * 2017-07-05 2020-04-17 浙江大学 2-氨基咪唑并吡啶类衍生物及制备和应用
CN111315735B (zh) * 2017-09-04 2024-03-08 C4医药公司 二氢苯并咪唑酮
EP3693360B1 (en) 2017-10-06 2023-12-13 Takeda Pharmaceutical Company Limited Heterocyclic compounds
PT3860998T (pt) 2018-10-05 2024-04-02 Annapurna Bio Inc Compostos e composições para o tratamento de condições associadas à atividade do recetor apj
JP2022510501A (ja) * 2018-10-30 2022-01-26 リペア セラピューティクス インコーポレイテッド 化合物、医薬組成物、ならびに化合物の調製方法及びａｔｒキナーゼ阻害剤としてのその使用方法
MX2021009667A (es) 2019-02-13 2021-12-10 Ptc Therapeutics Inc Compuestos de tioeno[3,2-b] piridin-7-amina para tratar la disautonomía familiar.
WO2020167624A1 (en) 2019-02-13 2020-08-20 Ptc Therapeutics, Inc. Pyrrolo[2,3-d]pyrimidine compounds for treating familial dysautonomia
ES2995214T3 (en) 2019-03-06 2025-02-07 C4 Therapeutics Inc Heterocyclic compounds for medical treatment
AU2020317381A1 (en) * 2019-07-22 2022-02-10 Repare Therapeutics Inc. Substituted 2-morpholinopyridine derivatives as ATR kinase inhibitors
EP4263523A2 (en) * 2020-12-16 2023-10-25 IFM Due, Inc. Compounds and compositions for treating conditions associated with sting activity
CN114591338B (zh) * 2022-03-31 2023-05-09 苏州欧康维视生物科技有限公司 一种Syk和VEGFR2双靶点抑制剂的制备方法及其用途
CN115304599A (zh) * 2022-09-20 2022-11-08 浙大宁波理工学院 一种3-溴-6-异丙基-1氢-哌咯[2，3-b]并吡啶及其制备方法
CN117402148A (zh) * 2023-07-26 2024-01-16 青岛大学 一种氮-氮苯并咪唑轴手性化合物及其制备方法和应用
KR20250113344A (ko) * 2024-01-17 2025-07-25 주식회사 엘지화학 CBP/p300 저해제로 사용되는 신규 화합물, 및 이를 유효성분으로 포함하는 암, 염증성 장애 또는 자가면역 질환의 예방 또는 치료용 약학 조성물
WO2025155830A1 (en) 2024-01-17 2025-07-24 Rapport Therapeutics, Inc. Crystalline forms of 3-(7-chloro-1h-indazol-5-yl)-2,5-bis(trifluoromethyl)-3h-imidazo[4,5-b]pyridine and their use in the treatment of epilepsy
WO2025217330A1 (en) * 2024-04-10 2025-10-16 Terremoto Biosciences, Inc. Cysteine covalent modifiers of akt1 and uses thereof
WO2025231416A1 (en) * 2024-05-03 2025-11-06 Rapport Therapeutics, Inc. Methods of use of ampa receptor modulators

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55167282A (en) 1979-06-12 1980-12-26 Fujisawa Pharmaceut Co Ltd Piperazine derivative or its salt and its preparation
CN1051313A (zh) 1990-11-07 1991-05-15 鞍山市振东工业尼龙厂 尼龙球磨罐及其热装工艺
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
TW251284B (es) * 1992-11-02 1995-07-11 Pfizer
KR970701182A (ko) 1994-02-10 1997-03-17 스피겔 알렌 제이 벤조다이아제핀 수용체 부위의 작용물질 및 길항물질로서의 5-헤테로아릴인돌 유도체(5-heteroarylindole derivatives as benzodiazepine receptor site agonists and antagonists)
US5565483A (en) 1995-06-07 1996-10-15 Bristol-Myers Squibb Company 3-substituted oxindole derivatives as potassium channel modulators
UA54403C2 (uk) 1996-10-01 2003-03-17 Н'Юросерч А/С Похідні індол-2,3-діон-3-оксиму, фармацевтична композиція, спосіб лікування розладу чи захворювання ссавців, у тому числі людини та спосіб одержання похідних індол-2,3-діон-3-оксиму
WO1999045007A1 (en) 1998-03-06 1999-09-10 Janssen Pharmaceutica N.V. Crf antagonistic pyrazolo[4,3-b]pyridines
DE19812331A1 (de) 1998-03-20 1999-09-23 Merck Patent Gmbh Piperidinderivate
WO2000001376A2 (en) * 1998-07-02 2000-01-13 Eisai Co., Ltd Pharmaceutical compositions and their uses for treatment of demyelinating disorders
WO2000038519A1 (en) 1998-12-31 2000-07-06 Sugen, Inc. 3-heteroarylidenyl-2-indolinone compounds for modulating protein kinase activity and for use in cancer chemotherapy
GB0018473D0 (en) 2000-07-27 2000-09-13 Merck Sharp & Dohme Therapeutic agents
EP1309577A2 (en) 2000-08-11 2003-05-14 Eli Lilly And Company Heterocyclic sulfonamide derivatives and their use for potentiating glutamate receptor function
US6548576B1 (en) 2001-11-07 2003-04-15 Bourns, Inc. Epoxy formulation adapted to be used in conjunction with no-lead solder in electronic components
GT200500185A (es) 2004-08-09 2006-04-10 Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
JP5209311B2 (ja) * 2004-09-03 2013-06-12 メルク セローノ ソシエテ アノニム ピリジンメチレンアゾリジノン及びホスホイノシチド阻害剤としてのその使用
EP1943230B1 (en) 2005-09-30 2010-12-22 Glaxo Group Limited Compounds which have activity at m1 receptor and their uses in medicine
WO2007135529A2 (en) * 2006-05-23 2007-11-29 Pfizer Products Inc. Azabenzimidazolyl compounds as mglur2 potentiators
DE602007013450D1 (de) 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
WO2008113795A1 (en) 2007-03-20 2008-09-25 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
GB0711089D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
WO2009067607A2 (en) 2007-11-20 2009-05-28 Memory Pharmaceuticals Corporation Combinations of pde4 inhibitors and antipsychotics for the treatment of psychotic disorders
JP2011506335A (ja) 2007-12-06 2011-03-03 シェーリング コーポレイション γ−セクレターゼ調節剤
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
US20110312938A1 (en) * 2008-06-30 2011-12-22 Ironwood Pharmaceuticals, Inc. Pyrrolopyridine Carboxylic Acid Derivatives
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
GB0822425D0 (en) 2008-12-09 2009-01-14 Glaxo Group Ltd Compounds
GB0822981D0 (en) 2008-12-17 2009-01-21 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
WO2011056985A2 (en) 2009-11-04 2011-05-12 Gilead Sciences, Inc. Substituted heterocyclic compounds
MX2012009378A (es) 2010-02-11 2012-09-12 Univ Vanderbilt Compuestos de pirazolopiridina, pirazolopirazina, pirazolopirimidina, pirazolotiofeno y pirazolotiazol como potenciadores alostericos mglur4, composiciones y metodos para tratar disfunciones neurologicas.
EP2579717A4 (en) 2010-06-09 2013-12-11 Merck Sharp & Dohme POSITIVE ALLOSTERIC MODULATORS OF MGLUR2
MA34385B1 (fr) 2010-06-24 2013-07-03 Takeda Pharmaceutical Composés hétérocycliques condensés comme inhibiteurs de phosphodiestérases (pdes)
SI2603513T1 (sl) 2010-08-10 2020-07-31 Takeda Pharmaceutical Company Limited Heterociklična spojina in njena uporaba kot pozitivni alosterični modulator receptorja AMPA
WO2012021382A1 (en) 2010-08-12 2012-02-16 Merck Sharp & Dohme Corp. Positive allosteric modulators of mglur2
JP6014155B2 (ja) 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
WO2013130501A1 (en) 2012-03-01 2013-09-06 The Board Of Regents Of The University Of Texas System Bivalent ampa receptor positive allosteric modulators
GB201205669D0 (en) * 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
JO3225B1 (ar) 2012-11-27 2018-03-08 Lilly Co Eli 6-((s)-1-{1-[5-(2-هيدروكسي-إيثوكسي)-بيريدين-2-يل]-1h-بيرازول-3-يل}إيثيل)-3h-1 ، 3-بنزو ثيازول-2- أون باعتباره مضاد مستقبل ampa يعتمد على tarp- جاما 8
AP2015008663A0 (en) 2013-02-19 2015-08-31 Pfizer Azabenzimidazole compounds as inhibitors of PDE4 isozymes for the treatment of cns and other disorders
TW201609719A (zh) 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
UA122688C2 (uk) 2015-04-03 2020-12-28 Інсайт Корпорейшн Гетероциклічні сполуки як інгібітори lsd1
HRP20210403T1 (hr) 2015-04-29 2021-10-29 Janssen Pharmaceutica Nv Azabenzimidazoli i njihova uporaba kao modulatora ampa receptora
WO2018080918A1 (en) 2016-10-26 2018-05-03 Janssen Pharmaceutica Nv 3-aryl-2h-pyrazolo[4,3-b]pyridine compounds and their use as ampa receptor modulators
JP6953527B2 (ja) 2016-10-26 2021-10-27 ヤンセン ファーマシューティカ エヌ．ベー． 縮合二環ピリジン化合物、及びａｍｐａ受容体調節因子としてのそれらの使用
AU2017350688B2 (en) 2016-10-26 2021-04-01 Rapport Therapeutics, Inc. Fused azaheterocyclic compounds and their use as AMPA receptor modulators
CA3094609A1 (en) 2018-04-09 2019-10-17 Raqualia Pharma Inc. Fused cyclic urea derivatives as crhr2 antagonist
WO2020159285A1 (ko) 2019-02-01 2020-08-06 한미약품 주식회사 이미다조피리딘 유도체 화합물 및 이의 용도

Also Published As

Publication number Publication date
NZ736057A (en) 2023-08-25
SG11201708190UA (en) 2017-11-29
KR20240017991A (ko) 2024-02-08
US11312712B2 (en) 2022-04-26
PH12017501816B1 (en) 2023-07-19
MA41988A (fr) 2018-07-03
JO3654B1 (ar) 2020-08-27
ECSP17074645A (es) 2018-02-28
EA033281B1 (ru) 2019-09-30
WO2016176460A1 (en) 2016-11-03
EP3288940A1 (en) 2018-03-07
BR122023023802A2 (pt) 2023-12-26
CO2017011017A2 (es) 2018-03-20
SI3288940T1 (sl) 2021-07-30
US12304908B2 (en) 2025-05-20
ES2865330T3 (es) 2021-10-15
MX2017013886A (es) 2018-03-12
DK3288940T5 (da) 2021-09-20
US20210284641A1 (en) 2021-09-16
CR20170484A (es) 2018-02-26
US20180118740A1 (en) 2018-05-03
SMT202100222T1 (it) 2021-05-07
DK3288940T3 (da) 2021-05-25
AU2016255434B2 (en) 2020-05-14
PH12017501816A1 (en) 2018-04-23
AR104447A1 (es) 2017-07-19
JP2018518462A (ja) 2018-07-12
KR20170140382A (ko) 2017-12-20
EP4144736A1 (en) 2023-03-08
CN107835814B (zh) 2021-07-23
AU2020210231A1 (en) 2020-08-20
CA2983826A1 (en) 2016-11-03
PL3288940T3 (pl) 2021-07-12
ZA201708065B (en) 2019-09-25
EP4144736B1 (en) 2026-05-06
NI201700129A (es) 2019-05-10
JP2021042230A (ja) 2021-03-18
RS61688B1 (sr) 2021-05-31
EP3901153A1 (en) 2021-10-27
CN107835814A (zh) 2018-03-23
MA41988B1 (fr) 2021-03-31
AU2020210231B2 (en) 2021-07-22
TW201708217A (zh) 2017-03-01
IL254848A0 (en) 2017-12-31
US12145934B2 (en) 2024-11-19
MD3288940T2 (ro) 2021-08-31
HK1252249A1 (en) 2019-05-24
IL254848B (en) 2021-01-31
EP3288940B9 (en) 2021-07-21
EP3288940B1 (en) 2021-02-24
TWI706952B (zh) 2020-10-11
PT3288940T (pt) 2021-04-30
JP7026194B2 (ja) 2022-02-25
EA201792374A1 (ru) 2018-05-31
US20230114165A1 (en) 2023-04-13
MX376113B (es) 2025-03-07
HRP20210403T1 (hr) 2021-10-29
BR112017023147A2 (pt) 2018-07-10
US20250230157A1 (en) 2025-07-17
MY194104A (en) 2022-11-11
LT3288940T (lt) 2021-05-10
HUE053943T2 (hu) 2021-08-30
US20230110576A1 (en) 2023-04-13
US12139485B2 (en) 2024-11-12
NZ774642A (en) 2024-09-27
UA120304C2 (uk) 2019-11-11
JP6800886B2 (ja) 2020-12-16
CY1124059T1 (el) 2022-05-27
KR102782808B1 (ko) 2025-03-14
UY36654A (es) 2016-10-31
BR112017023147B1 (pt) 2024-04-30
AU2016255434C1 (en) 2021-09-23
AU2016255434A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CR20170484A (es) Azabenzimidazoles y su uso como moduladores del receptor ampa
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
MX380829B (es) Derivados de quinoxalina útiles como amortiguadaores de receptor del factor de crecimiento de fibroblastos (fgfr) cinasa.
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CR20150524A (es) Compuestos de heteroarilo y sus usos
CY1120935T1 (el) Νεες συνθεσεις, χρησεις και μεθοδοι για την παρασκευη αυτων
MX381160B (es) Agonistas del receptor de apelina y metodos de uso.
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
CR20160374A (es) Ciclopentanos sustituidos en 1,2 como antagonistas del receptor de orexina
CL2019001330A1 (es) Inhibidores de la tirosina quinasa de bruton.
MX2017000183A (es) Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides.
MX378389B (es) Compuestos de bencimidazolona y benzotiazolona y su uso como moduladores del receptor ampa.
CO2019004164A2 (es) Compuestos de piridina bicíclicos fusionados y su uso como moduladores de receptores ampa
MX374555B (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
CL2020001062A1 (es) Sulfonas y sulfóxidos bicíclicos y métodos de uso de los mismos.
MX2016010524A (es) Derivados de piridazina para uso en la prevencion o tratamiento de trastorno ataxico.
CO2019004143A2 (es) Compuestos azaheterocíclicos fusionados y su uso como moduladores de los receptores ampa
CR20160373A (es) Ciclopentanos, tetrahidrofuranos y pirrolidinas sustituidas como antagonistas del receptor de orexina
MX369806B (es) Compuestos de indolona y su uso como moduladores del receptor ampa.
CR20140051A (es) Compuestos de tiazol y oxazol de bencen-sulfonamida
CR20190028A (es) Compuestos heterocíclicos como inmunomoduladores